ArticleTrends in molecular medicine2012
Targeted nanotherapy for induction of therapeutic immune responses.
Article in Trends in molecular medicine, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Nanocarriers for targeted drug delivery in the vascular system: focus on endothelium.Journal of nanobiotechnology · 2024Review
- Development of protein-polymer conjugate nanoparticles for modulation of dendritic cell phenotype and antigen-specific CD4 T cell responses.ACS applied polymer materials · 2023Article
- Article
- Article
- Strategies to Use Nanoparticles to Generate CD4 and CD8 Regulatory T Cells for the Treatment of SLE and Other Autoimmune Diseases.Frontiers in immunology · 2021Review
- Multiple Sclerosis: LIFNano-CD4 for Trojan Horse Delivery of the Neuro-Protective Biologic "LIF" Into the Brain: Preclinical Proof of Concept.Frontiers in medical technology · 2021Article
- Severe Acute Respiratory Syndrome Coronavirus-2 Spike Protein Nanogel as a Pro-Antigen Strategy with Enhanced Protective Immune Responses.Small (Weinheim an der Bergstrasse, Germany) · 2020Article
- Rebalancing Immune Homeostasis to Treat Autoimmune Diseases.Trends in immunology · 2019Review
- Article
- Nanoparticles for the Induction of Antigen-Specific Immunological Tolerance.Frontiers in immunology · 2018Review
- Multipeptide-coupled nanoparticles induce tolerance in 'humanised' HLA-transgenic mice and inhibit diabetogenic CD8Diabetologia · 2017Article
- Drug nanocarriers to treat autoimmunity and chronic inflammatory diseases.Seminars in immunology · 2017Review
- Neurodegenerative Disease: A Perspective on Cell-Based Therapy in the New Era of Cell-Free Nano-Therapy.Current pharmaceutical design · 2017Review
- Employing Escherichia coli-derived outer membrane vesicles as an antigen delivery platform elicits protective immunity against Acinetobacter baumannii infection.Scientific reports · 2016Article
- Improving the efficacy and safety of biologic drugs with tolerogenic nanoparticles.Nature nanotechnology · 2016Article
- Myelin repair in vivo is increased by targeting oligodendrocyte precursor cells with nanoparticles encapsulating leukaemia inhibitory factor (LIF).Biomaterials · 2015Article
- Targeting T cell metabolism for therapy.Trends in immunology · 2015Review
- Polymeric synthetic nanoparticles for the induction of antigen-specific immunological tolerance.Proceedings of the National Academy of Sciences of the United States of America · 2015Article
- Nanoparticle-mediated combinatorial targeting of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via IL-15-dependent DC crosstalk.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigm.ACS nano · 2014Review
Corrections and comments
- Commented on by
Authors and funding
2 authors.
Funding
Abstract
Nanotechnology permits the design of therapeutic devices with defined structure and molecular composition. Modular designs employing surface-bound ligands provide specific homing devices for loaded cargo, and biocompatible and biodegradable constructs provide surrogate temporary microenvironments. We first present a case for developing 'smart' modular constructs as immunogenic vaccines to prime immune memory against specific pathogens where current vaccines fail. Second, we argue that nanotherapeutic intervention can harness pivotal molecular pathways recently discovered to regulate lineage development between pathogenic TH17 cells associated with autoimmune disease, versus tolerogenic regulatory T cells (Treg). Underpinned by molecular mechanisms that enable exquisitely specific responses in adaptive immunity, targeted nanodevices designed to stimulate either immune aggression or immune tolerance signify the birth of a new era in therapeutics.
Indexed as
Identifiers
22172276What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.